Consider clinically relevant drug interactions when prescribing edoxaban

被引：0

作者：

Kim, Esther S. ^{[1
]}

Heo, Young-A ^{[1
]}

机构：

[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand

来源：

DRUGS & THERAPY PERSPECTIVES | 2021年 / 37卷 / 03期

关键词：

XA INHIBITOR EDOXABAN; PHARMACOKINETICS; PHARMACODYNAMICS; ASPIRIN; SAFETY;

D O I：

10.1007/s40267-020-00805-y

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Edoxaban, a factor Xa inhibitor, is a direct oral anticoagulant (DOAC). DOACs may have a lower incidence of drug-drug interactions (DDIs) than vitamin K antagonists such as warfarin. Nonetheless, DOACs can have clinically relevant pharmacokinetic and pharmacodynamic DDIs. Careful consideration of potential DDIs is needed when prescribing edoxaban, and clinically relevant DDIs may be prevented by avoiding offending combinations, spacing out the timing of the drugs or by halving the dose of edoxaban where indicated.

引用

页码：115 / 119

页数：5

共 50 条

[1] Consider clinically relevant drug interactions when prescribing edoxaban
Esther S. Kim
Young-A Heo
Drugs & Therapy Perspectives, 2021, 37 : 115 - 119
[2] Consider clinically relevant pharmacokinetic drug interactions when co-prescribing drugs in attention-deficit/hyperactivity disorder
Esther Kim
Young-A. Heo
Drugs & Therapy Perspectives, 2020, 36 : 386 - 388
[3] Consider clinically relevant pharmacokinetic drug interactions when co-prescribing drugs in attention-deficit/hyperactivity disorder
Kim, Esther
Heo, Young-A.
DRUGS & THERAPY PERSPECTIVES, 2020, 36 (09) : 386 - 388
[4] Clinically relevant new drug interactions
Fuhr, U
MEDIZINISCHE KLINIK, 1999, 94 (02) : 120 - 124
[5] Clinically relevant new drug interactions
Fuhr, U
MEDIZINISCHE KLINIK, 2000, 95 : 18 - 22
[6] CLINICALLY RELEVANT DRUG-INTERACTIONS
HENGSTMANN, JH
MEDIZINISCHE WELT, 1981, 32 (07): : 232 - 233
[7] No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin
Derks, Michael
Abt, Markus
Parr, Graeme
Meneses-Lorente, Georgina
Young, Anne-Marie
Phelan, Mary
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (10) : 1135 - 1145
[8] Consider the risk of potential drug interactions when co-prescribing triptans with other medications
Adis Medical Writers
Drugs & Therapy Perspectives, 2013, 29 (5) : 151 - 154
[9] Detrimental Antidepressant Drug–Drug Interactions: Are They Clinically Relevant?
Sheldon Preskorn
Steve Werder
Neuropsychopharmacology, 2006, 31 : 1605 - 1612
[10] Clinically relevant drug-drug interactions in oncology
McLeod, HL
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (06) : 539 - 544

← 1 2 3 4 5 →